C.E, Drechsel Katja
C., van Tilborg Theodora
J.C., Eijkemans Marinus
G.W.M., Lentjes Eef
Irene, Homminga
Mariette, Goddijn
J.T., van Golde Ron
Willem, Verpoest
D., Lichtenbelt Klaske
J.M., Broekmans Frank
M.E., Bos Anna
Funding for this research was provided by:
Ferring Pharmaceuticals
Article History
Received: 12 January 2022
Accepted: 2 June 2022
First Online: 15 June 2022
Declarations
:
: This study, evaluating BRCA mutations and ovarian ageing in women applying for in vitro fertilization and preimplantation genetic diagnosis (acronym BROCA2), is registered in the Netherlands Trial Register (Trial NL4347, NTR4703). The study was approved by the UMCU Ethical Committee (METC 14–175) and by the Ethical Committees of all the participating centres.
: All participants gave their written informed consent.
: All participants gave their written informed consent.
: KD, TvT, ME, EL, IH, RG, WV, KL and AB have nothing to disclose. FB is a Member of the external advisory board for Merck Serono and has received grants and personal fees outside the submitted work. MG declares that the Center for Reproductive Medicine, Amsterdam UMC (location VUMC) has received several research and educational grants from Guerbet, Merck and Ferring, not related to the presented work.